Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

By afschroeder • September 17, 2026

Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin Y, Ko M, Sayar E, Patton RD, Kollath L, Meis A, Lindergren S, Ji N, Ali K, Venkatesh H, Wladyka CL, McDeed AP, Mills CB, Vashisth M, Kim JY, Nadal R, Hawley JE, Yezefski TA, Psutka SP, Gore JL, Lin DW, Nelson PS, Cheng HH, Schweizer MT, Fong L, Lee JK, Yu EY, Corey E, Morrissey C, Grivas P, Montgomery RB, Wright JL, Haffner MC, Vakar-Lopez F, Mian OY, Lam HM, Hsieh AC, Ha G. Evolution and heterogeneity of lethal metastatic bladder cancer subtypes. Nature. 2026 Sep 16. doi: 10.1038/s41586-026-11035-z. Epub ahead of print. PMID: 42749807.

Tags: Hematology/Oncology, Publications

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]